Navigation Links
Tysabri May Cause Liver Damage, Health Officials Say
Date:2/27/2008

MS drug also used to treat Crohn's disease can show injury in as little as 6 days

WEDNESDAY, Feb. 27 (HealthDay News) -- The controversial multiple sclerosis drug Tysabri can start causing liver damage within six days of the first dose, U.S. health officials said Wednesday.

In January, the U.S. Food and Drug Administration expanded the use of Tysabri to treat Crohn's disease, a chronic inflammation of the digestive tract.

The drug has also been linked with serious brain infections in multiple sclerosis patients, as well as liver damage.

When the FDA granted approval to use Tysabri for Crohn's disease, it asked the manufacturers -- Biogen Idec of Cambridge, Mass., and Elan Corp. -- to send letters to health-care providers about the potential problems with liver toxicity.

"This [the Biogen Idec letter] was part of the approval of Jan. 14," said FDA spokeswoman Rita Chappelle. "The manufacturer was going to send out a notice to health-care providers to make them aware of the potential problem."

A warning about the danger of Tysabri to the liver is already on the product label.

"FDA does not require 'Dear Doctor Letters,' but can request that a sponsor send one to inform health-care practitioners about new adverse events that are labeled," Chappelle added.

According to the letter from Biogen Idec, the drug should be stopped or discontinued if patients become jaundiced or have other evidence of liver damage.

Tysabri (natalizumab), a monoclonal antibody used to treat MS, has been under a cloud of controversy for some time. The drug works by attaching itself to white blood cells called lymphocytes and preventing them from entering the brain, where they do damage that causes the disabling symptoms of MS.

But the drug has a checkered past. It first received FDA approval in November 2004, only to be pulled from the market three months later, after several patients in clinical trials developed a rare but deadly viral infection of the brain called progressive multifocal leukoencephalopathy.

In June 2006, the FDA allowed the drug back on the market but with strict conditions. According to those revised guidelines, Tysabri can only be administered by approved doctors, at infusion sites and pharmacies that register and comply with a patient-safety program called CD Touch, designed by Biogen Idec and approved by the FDA.

More information

For more on Tysabri, visit the U.S. Food and Drug Administration.



SOURCE: Rita Chappelle, spokeswoman, U.S. Food and Drug Administration


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Stopping Tysabri May Worsen MS
2. MS Drug Tysabri Approved for Crohns Disease
3. Drug for cluster headaches may cause heart problems
4. Study Points to Cause of Vioxx Heart Risk
5. Damp, Moldy Homes May Cause Depression
6. Constipations Many Causes and Cures
7. High Co-Pays Cause Seniors to Go Without Meds
8. 13 percent of women stop taking breast cancer drug because of side effects, U-M study finds
9. Vocal cord dysfunction may be caused by work
10. Study finds drug spending caps cause some seniors to quit taking key medicines
11. Medicare Spending Caps Cause Seniors to Stop Meds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Tysabri May Cause Liver Damage, Health Officials Say
(Date:2/24/2017)... ... February 24, 2017 , ... ... disabilities, it is so critically important that we all are aware of our ... why Mediaplanet is proud to announce the launch of its newest edition of ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... With ProGlass ... Cut Pro X . Users have total control over position, rotation, distortion, edge softness, ... all within Final Cut Pro X. , With ProGlass Prism users are given the ...
(Date:2/24/2017)... ... February 24, 2017 , ... The International Association of Eating Disorders Professionals ... What You See” body image mannequin art competition. Selected from 15 submissions from around ... winner revealed at the 31st annual iaedp Symposium, March 22 – 26 in Las ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... services, which specializes in thought leadership , media relations, social media, content ... services that will be powered through Act-On, an intuitive marketing automation platform. , ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... an official 2017 partnership with The Jensie Gran Fondo of Marin. For the ... UVB rays with Thinksport’s broad-spectrum, mineral-based sunscreen. , “We are thrilled to provide ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... Research and Markets has announced the addition of the "Dry ... offering. ... Dry eye Drugs Price Analysis and Strategies - 2016, provides drug pricing ... answers the following questions: What are the ... they positioned in the Global Dry eye market? What ...
(Date:2/24/2017)... CUPERTINO, Calif. , Feb. 24, 2017  In ... fourth quarter 2016 financial results press release, you are ... be broadcast live over the internet on Tuesday, March ... Pacific Time). A live audio webcast of ... at www.durect.com and clicking "Investor Relations."  If ...
(Date:2/24/2017)... NEW YORK , Feb. 24, 2017 ... Monteverde & Associates PC , a boutique securities ... New York City , announces that a ... of Massachusetts  against Inotek Pharmaceuticals ... purchasers of the Company,s securities between July 23, 2015 and ...
Breaking Medicine Technology: